Go Pro
→ Sell Tesla, Buy the New King of FSD Cars (From Chaikin Analytics) (Ad)tc pixel Free SLN Stock Alerts

Silence Therapeutics (SLN) Financials

Silence Therapeutics logo
$9.09 -0.77 (-7.81%)
Closing price 04:00 PM Eastern
Extended Trading
$9.09 0.00 (-0.06%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Silence Therapeutics

Annual Income Statements for Silence Therapeutics

This table shows Silence Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -23 -26 -44 -53 -50 -54 -45 -89
Consolidated Net Income / (Loss)		 -23 -26 -44 -53 -50 -54 -45 -89
Net Income / (Loss) Continuing Operations		 -23 -26 -44 -53 -50 -54 -45 -89
Total Pre-Tax Income 		-26 -30 -49 -62 -50 -53 -44 -89
Total Operating Income		 -26 -30 -49 -62 -61 -64 -63 -91
Total Gross Profit		 0.00 0.32 2.34 6.69 8.19 19 31 0.34
Total Revenue		 0.00 0.32 7.48 17 22 32 43 0.56
Operating Revenue		 0.00 0.32 7.48 17 22 32 43 0.56
Total Cost of Revenue		 0.00 0.00 5.14 10 13 13 12 0.22
Operating Cost of Revenue		 0.00 0.00 5.14 10 13 13 12 0.22
Total Operating Expenses		 26 30 51 69 69 83 95 91
Selling, General & Admin Expense		 14 13 19 27 26 26 27 22
Research & Development Expense		 12 18 28 42 44 57 68 68
Restructuring Charge		 - - - - - - 0.00 1.32
Total Other Income / (Expense), net		 0.05 -0.18 -0.26 -0.06 11 11 19 2.48
Interest Expense		 0.00 0.22 0.44 0.07 -9.82 -12 -14 -7.46
Other Income / (Expense), net		 - - - - 1.57 -0.84 5.12 -4.99
Income Tax Expense		 -2.69 -4.36 -4.77 -8.70 0.69 0.96 0.85 0.01
Basic Earnings per Share		 ($0.26) - - - ($0.52) ($0.49) ($0.33) ($0.63)
Weighted Average Basic Shares Outstanding		 - - 83.31M 89.78M 96.58M 111.28M 138.75M 141.69M
Diluted Earnings per Share		 ($0.26) - - - ($0.52) ($0.49) ($0.33) ($0.63)
Weighted Average Diluted Shares Outstanding		 - - 83.31M 89.78M 96.58M 111.28M 138.75M 141.69M
Weighted Average Basic & Diluted Shares Outstanding		 - - 83.31M 89.78M 107.81M 118.85M 141.67M 141.70M

Quarterly Income Statements for Silence Therapeutics

This table shows Silence Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.31 -20 -36 12 -29 -27 -21 -12 -15
Consolidated Net Income / (Loss)		 -2.31 -20 -36 12 -29 -27 -21 -12 -15
Net Income / (Loss) Continuing Operations		 -2.31 -20 -36 12 -29 -27 -21 -12 -15
Total Pre-Tax Income 		-2.07 -20 -35 13 -29 -27 -21 -12 -15
Total Operating Income		 -5.58 -23 -30 -4.35 -28 -24 -26 -12 -16
Total Gross Profit		 13 -2.58 -2.14 23 0.09 0.14 0.10 0.02 0.41
Total Revenue		 16 0.76 1.50 25 0.14 0.22 0.16 0.03 0.42
Operating Revenue		 16 0.76 1.50 25 0.14 0.22 0.16 0.03 0.42
Total Cost of Revenue		 2.80 3.33 3.64 2.04 0.05 0.09 0.06 0.01 0.01
Operating Cost of Revenue		 2.80 3.33 3.64 2.04 0.05 0.09 0.06 0.01 0.01
Total Operating Expenses		 18 21 28 28 28 24 26 12 16
Selling, General & Admin Expense		 6.64 7.01 7.70 5.54 7.68 5.13 5.80 3.73 7.03
Research & Development Expense		 12 14 20 22 21 18 21 8.75 9.12
Restructuring Charge		 - 0.00 0.00 - 0.00 1.32 0.00 - 0.00
Total Other Income / (Expense), net		 3.51 3.86 -5.50 17 -0.12 -3.38 5.29 0.69 0.78
Interest Expense		 -2.50 -2.73 -4.49 -4.02 -2.68 -2.37 -2.58 0.17 -0.69
Other Income / (Expense), net		 1.02 1.13 -9.98 13 -2.80 -5.75 2.70 0.86 0.09
Income Tax Expense		 0.24 0.23 0.05 0.32 0.00 0.01 0.00 - 0.00
Basic Earnings per Share		 ($0.02) ($0.14) ($0.25) $0.08 ($0.20) ($0.19) ($0.15) ($0.09) ($0.11)
Weighted Average Basic Shares Outstanding		 131.88M 140.21M 141.20M 138.75M 141.68M 141.70M 141.70M 141.69M 141.70M
Diluted Earnings per Share		 ($0.02) ($0.14) ($0.25) $0.08 ($0.20) ($0.19) ($0.15) ($0.09) ($0.11)
Weighted Average Diluted Shares Outstanding		 131.88M 140.21M 141.20M 138.75M 141.68M 141.70M 141.70M 141.69M 141.70M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 141.67M 141.69M 141.70M 141.70M 141.70M 141.70M

Annual Cash Flow Statements for Silence Therapeutics

This table details how cash moves in and out of Silence Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -27 13 24 62 -25 1.77 52 -110
Net Cash From Operating Activities		 -21 5.60 3.20 64 -57 -49 -68 -62
Net Cash From Continuing Operating Activities		 -22 5.60 3.20 64 -57 -49 -68 -62
Net Income / (Loss) Continuing Operations		 -26 0.00 0.00 0.00 -50 -54 -45 -89
Consolidated Net Income / (Loss)		 -26 - - - -50 -54 -45 -89
Depreciation Expense		 0.48 0.60 0.65 - 0.38 0.37 0.34 0.31
Amortization Expense		 0.00 - 0.03 - 0.22 0.25 0.26 0.24
Non-Cash Adjustments To Reconcile Net Income		 0.88 0.96 2.53 51 1.58 15 6.92 20
Changes in Operating Assets and Liabilities, net		 2.34 4.05 - 14 -8.89 -11 -30 6.13
Net Cash From Investing Activities		 -6.15 -0.01 0.00 -1.77 -20 19 -22 -48
Net Cash From Continuing Investing Activities		 0.17 -0.01 0.00 -1.77 -20 19 -22 -48
Purchase of Property, Plant & Equipment		 -0.17 -0.01 - -1.77 -0.17 -0.06 -0.21 -0.06
Acquisitions		 - - - - -0.37 0.00 0.00 0.00
Other Investing Activities, net		 - - - - -20 19 -22 -48
Net Cash From Financing Activities		 0.43 6.99 21 0.00 53 32 142 0.02
Net Cash From Continuing Financing Activities		 0.43 6.99 21 0.00 53 32 142 0.02
Issuance of Common Equity		 0.43 6.99 - - 53 32 142 0.02
Other Net Changes in Cash		 - - - -0.14 - - 0.06 0.20
Cash Income Taxes Paid		 - - - - 0.00 -0.80 0.43 0.64

Quarterly Cash Flow Statements for Silence Therapeutics

This table details how cash moves in and out of Silence Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 74 -4.26 -56 39 -57 -23 40 -71 -5.60
Net Cash From Operating Activities		 -9.14 -5.41 -26 -27 -12 -22 -11 -17 -16
Net Cash From Continuing Operating Activities		 -9.14 -5.41 -26 -27 -12 -22 -11 -17 -16
Net Income / (Loss) Continuing Operations		 -2.31 -20 -36 12 -29 -27 -21 -12 -15
Consolidated Net Income / (Loss)		 -2.31 -20 -36 12 -29 -27 -21 -12 -15
Depreciation Expense		 0.09 0.09 0.09 0.08 0.07 0.08 0.08 0.08 0.07
Amortization Expense		 0.06 0.06 0.07 0.06 0.07 0.07 0.08 0.04 0.03
Non-Cash Adjustments To Reconcile Net Income		 12 0.29 8.34 -14 14 7.92 -1.65 -0.55 1.69
Changes in Operating Assets and Liabilities, net		 -19 14 1.45 -26 2.15 -2.50 12 -5.08 -2.45
Net Cash From Investing Activities		 -50 -0.04 -38 66 -44 -1.56 51 -53 10
Net Cash From Continuing Investing Activities		 -50 -0.04 -38 66 -44 -1.56 51 -53 10
Purchase of Property, Plant & Equipment		 0.00 -0.09 -0.06 -0.06 -0.00 -0.05 -0.00 - 0.00
Acquisitions		 0.00 - - - 0.00 - - - 0.00
Other Investing Activities, net		 -50 0.04 -38 66 -44 -1.51 51 -53 10
Net Cash From Financing Activities		 133 1.19 7.97 -0.10 0.01 0.00 - - 0.00
Net Cash From Continuing Financing Activities		 133 1.19 7.97 -0.10 0.01 0.00 - - 0.00
Issuance of Common Equity		 133 1.19 7.97 -0.10 0.01 0.00 - - 0.00
Other Net Changes in Cash		 -0.04 -0.01 - - 0.23 0.20 -0.11 -0.13 -0.02
Cash Income Taxes Paid		 -0.11 -0.11 -0.11 0.76 -0.08 -0.43 -0.12 1.27 -0.09

Annual Balance Sheets for Silence Therapeutics

This table presents Silence Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 56 88 117 130 130 119 203 131
Total Current Assets		 38 50 104 117 117 103 187 119
Cash & Equivalents		 27 18 37 99 66 69 121 11
Short-Term Investments		 13 53 16 0.00 20 0.00 26 74
Accounts Receivable		 0.00 0.01 40 0.45 1.11 0.29 0.97 0.00
Other Current Assets		 1.12 1.17 6.30 7.45 12 34 39 34
Plant, Property, & Equipment, net		 1.17 0.81 1.54 2.62 2.66 1.94 1.82 1.58
Total Noncurrent Assets		 11 11 12 11 10 14 13 11
Goodwill		 10 10 11 10 9.67 9.98 9.39 11
Intangible Assets		 0.08 0.05 0.02 0.03 0.39 0.36 0.31 0.29
Other Noncurrent Operating Assets		 - - - - 0.00 4.02 3.75 0.29
Total Liabilities & Shareholders' Equity		 50 61 117 130 130 119 203 131
Total Liabilities		 4.88 33 105 118 103 97 69 69
Total Current Liabilities		 4.88 13 35 20 27 22 17 14
Accounts Payable		 4.88 9.13 11 15 15 16 16 13
Other Current Liabilities		 0.00 3.66 24 5.92 11 6.80 0.42 0.26
Total Noncurrent Liabilities		 0.00 21 70 98 77 75 52 56
Other Noncurrent Operating Liabilities		 0.00 21 70 98 77 75 52 56
Commitments & Contingencies		 - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 45 28 12 12 27 22 134 62
Total Preferred & Common Equity		 45 28 12 12 27 22 134 62
Total Common Equity		 45 28 12 12 27 22 134 62
Common Stock		 4.53 5.19 5.69 6.06 6.51 465 620 628
Retained Earnings		 -170 -201 -252 -301 -318 -432 -474 -563
Accumulated Other Comprehensive Income / (Loss)		 - - - - - -11 -12 -2.98

Quarterly Balance Sheets for Silence Therapeutics

This table presents Silence Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 185 165 147 115
Total Current Assets		 170 149 134 103
Cash & Equivalents		 65 42 82 5.66
Short-Term Investments		 72 72 20 64
Accounts Receivable		 0.04 0.09 0.03 0.00
Other Current Assets		 33 34 31 33
Plant, Property, & Equipment, net		 1.69 1.78 1.66 1.40
Total Noncurrent Assets		 14 15 12 11
Goodwill		 9.78 11 11 10
Intangible Assets		 0.31 0.32 0.30 0.25
Other Noncurrent Operating Assets		 3.72 3.97 0.59 0.27
Total Liabilities & Shareholders' Equity		 185 165 147 115
Total Liabilities		 73 71 73 66
Total Current Liabilities		 19 15 17 10
Accounts Payable		 19 14 17 10
Other Current Liabilities		 0.45 0.46 0.39 0.09
Total Noncurrent Liabilities		 53 56 55 55
Other Noncurrent Operating Liabilities		 53 56 55 55
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 113 94 74 49
Total Preferred & Common Equity		 113 94 74 49
Total Common Equity		 113 94 74 49
Common Stock		 623 625 628 630
Retained Earnings		 -503 -530 -551 -578
Accumulated Other Comprehensive Income / (Loss)		 -8.08 -1.40 -3.07 -3.37

Annual Metrics And Ratios for Silence Therapeutics

This table displays calculated financial ratios and metrics derived from Silence Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 83,306,259.00 89,784,720.00 107,808,471.00 118,846,966.00 - 141,701,848.00
DEI Adjusted Shares Outstanding		 0.00 0.00 83,306,259.00 89,784,720.00 107,808,471.00 118,846,966.00 - 141,701,848.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.53 -0.59 -0.47 -0.46 - -0.63
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 2,214.34% 123.99% 29.20% 46.12% 36.71% -98.71%
EBITDA Growth		 0.00% -14.81% -63.52% -28.11% 4.82% -9.73% 10.82% -65.79%
EBIT Growth		 0.00% -14.98% -62.52% -26.33% 3.85% -9.68% 10.76% -65.06%
NOPAT Growth		 0.00% -14.98% -62.52% -26.33% 1.31% -5.48% 1.65% -43.84%
Net Income Growth		 0.00% -10.63% -71.31% -19.69% 5.39% -7.74% 16.45% -95.57%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 5.77% 32.65% -90.91%
Operating Cash Flow Growth		 0.00% 126.24% -42.84% 1,902.03% -188.97% 13.29% -36.75% 7.94%
Free Cash Flow Firm Growth		 0.00% 0.00% -256.00% 136.11% -2,051.59% 18.81% -34.43% 30.27%
Invested Capital Growth		 0.00% -262.55% -141.50% -113.88% 32.40% 21.49% 71.56% -71.36%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -97.84%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -26.87%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -26.63%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9.77%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -37.30%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -36.96%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 14.07%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 18.91%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 100.00% 31.34% 39.94% 37.83% 59.34% 72.70% 61.54%
EBITDA Margin		 0.00% -9,131.95% -645.21% -369.02% -271.85% -204.15% -133.17% -17,085.69%
Operating Margin		 0.00% -9,317.20% -654.26% -369.02% -281.87% -203.47% -146.38% -16,292.84%
EBIT Margin		 0.00% -9,317.20% -654.26% -369.02% -274.61% -206.12% -134.54% -17,184.97%
Profit (Net Income) Margin		 0.00% -8,025.40% -594.03% -317.44% -232.44% -171.37% -104.74% -15,851.88%
Tax Burden Percent		 89.70% 85.62% 90.31% 85.94% 101.39% 101.79% 101.90% 100.01%
Interest Burden Percent		 99.81% 100.60% 100.54% 100.09% 83.49% 81.68% 76.40% 92.23%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -52.52% -71.71% -221.82% -445.55% -263.76% -222.93% -58.08% -90.27%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -41.98% -47.77% -50.02% -45.80% -52.33% -36.14% -57.51%
Return on Assets (ROA)		 0.00% -36.16% -43.37% -43.03% -38.76% -43.51% -28.14% -53.05%
Return on Common Equity (ROCE)		 -52.52% -71.71% -221.82% -445.55% -263.76% -222.93% -58.08% -90.27%
Return on Equity Simple (ROE_SIMPLE)		 -52.52% -93.65% -359.28% -462.23% -188.83% -246.57% -33.81% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -21 -34 -43 -43 -45 -44 -64
NOPAT Margin		 0.00% -6,522.04% -457.98% -258.31% -197.31% -142.43% -102.46% -11,404.99%
Net Nonoperating Expense Percent (NNEP)		 -14.98% -12.32% -20.70% -12.93% -8.18% -11.82% -0.91% -21.39%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -160.29% -204.92% -33.07% -102.33%
Cost of Revenue to Revenue		 0.00% 0.00% 68.66% 60.06% 62.17% 40.66% 27.30% 38.46%
SG&A Expenses to Revenue		 0.00% 3,951.63% 255.21% 161.16% 118.60% 82.87% 62.15% 3,997.14%
R&D to Revenue		 0.00% 5,465.57% 368.84% 247.81% 201.11% 179.94% 156.93% 12,120.39%
Operating Expenses to Revenue		 0.00% 9,417.20% 685.60% 408.96% 319.70% 262.80% 219.07% 16,354.38%
Earnings before Interest and Taxes (EBIT)		 -26 -30 -49 -62 -59 -65 -58 -96
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 -30 -48 -62 -59 -65 -58 -96
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 57.64 17.12 28.38 2.03 4.61
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 540.00 27.50 53.58 2.19 5.59
Price to Revenue (P/Rev)		 0.00 0.00 0.00 39.58 21.08 19.73 6.30 513.74
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 33.63 17.09 17.55 2.89 361.48
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 8.79 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 154.31 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.76 -1.09 -2.45 -6.42 -4.87 -3.19 -1.39 -1.18
Leverage Ratio		 1.25 1.98 5.11 10.35 6.80 5.12 2.06 1.70
Compound Leverage Factor		 1.25 2.00 5.14 10.36 5.68 4.19 1.58 1.57
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -0.44 -1.28 -1.94 -0.62 -4.95
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 7.70 3.88 2.99 5.69 4.41 4.62 11.14 8.72
Quick Ratio		 8.25 5.54 2.67 4.87 3.28 3.09 8.82 6.25
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 6.48 -10 3.65 -71 -58 -78 -54
Operating Cash Flow to CapEx		 -12,892.34% 46,976.68% 0.00% 3,622.73% -32,973.41% -88,325.00% -32,056.87% -113,220.00%
Free Cash Flow to Firm to Interest Expense		 0.00 30.02 -22.93 52.04 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 25.94 7.26 913.35 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 25.88 7.26 888.13 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.07 0.14 0.17 0.25 0.27 0.00
Accounts Receivable Turnover		 0.00 0.00 0.37 0.83 27.91 45.36 68.55 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.33 6.37 8.05 8.20 13.77 23.03 0.33
Accounts Payable Turnover		 0.00 0.00 0.51 0.78 0.90 0.84 0.74 0.01
Days Sales Outstanding (DSO)		 0.00 0.00 976.28 440.68 13.08 8.05 5.32 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 721.61 466.78 404.15 436.77 493.51 25,257.15
Cash Conversion Cycle (CCC)		 0.00 0.00 254.67 -26.11 -391.07 -428.72 -488.18 -25,257.15
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 11 -17 -41 -88 -60 -47 -13 -23
Invested Capital Turnover		 0.00 -0.10 -0.26 -0.26 -0.29 -0.59 -1.44 -0.03
Increase / (Decrease) in Invested Capital		 0.00 -28 -24 -47 29 13 33 -9.50
Enterprise Value (EV)		 0.00 0.00 0.00 564 370 555 125 202
Market Capitalization		 0.00 0.00 0.00 663 456 624 273 287
Book Value per Share		 $0.00 $0.00 $0.15 $0.14 $0.30 $0.20 $1.13 $0.44
Tangible Book Value per Share		 $0.00 $0.00 $0.02 $0.01 $0.18 $0.11 $1.05 $0.36
Total Capital		 45 28 12 12 27 22 134 62
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -41 -71 -54 -100 -86 -69 -147 -85
Capital Expenditures (CapEx)		 0.17 0.01 0.00 1.77 0.17 0.06 0.21 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.53 -34 16 -3.20 4.35 12 23 20
Debt-free Net Working Capital (DFNWC)		 33 37 69 96 90 81 171 105
Net Working Capital (NWC)		 33 37 69 96 90 81 171 105
Net Nonoperating Expense (NNE)		 5.12 4.86 10 9.91 7.61 9.16 0.99 25
Net Nonoperating Obligations (NNO)		 -34 -45 -54 -100 -86 -69 -147 -85
Total Depreciation and Amortization (D&A)		 0.48 0.60 0.68 0.00 0.60 0.62 0.59 0.56
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -10,534.82% 216.88% -19.10% 20.07% 38.01% 53.65% 3,565.47%
Debt-free Net Working Capital to Revenue		 0.00% 11,398.34% 927.61% 573.23% 416.84% 255.40% 394.25% 18,791.59%
Net Working Capital to Revenue		 0.00% 11,398.34% 927.61% 573.23% 416.84% 255.40% 394.25% 18,791.59%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.40) $0.00 $0.00 $0.00 ($0.33) ($0.63)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 83.31M 89.78M 107.81M 118.85M 138.75M 141.69M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.40) $0.00 $0.00 $0.00 ($0.33) ($0.63)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 83.31M 89.78M 107.81M 118.85M 138.75M 141.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($0.40) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 83.31M 89.78M 107.81M 118.85M 141.67M 141.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -21 -34 -43 -43 -45 -44 -63
Normalized NOPAT Margin		 0.00% -6,522.04% -457.98% -258.31% -197.31% -142.43% -102.46% -11,239.20%
Pre Tax Income Margin		 0.00% -9,372.94% -657.80% -369.36% -229.26% -168.35% -102.79% -15,849.91%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 -139.47 -110.98 -881.04 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -97.63 -77.69 -616.73 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -139.53 -110.98 -906.25 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -97.69 -77.69 -641.94 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Silence Therapeutics

This table displays calculated financial ratios and metrics derived from Silence Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 118,846,966.00 118,846,966.00 118,846,966.00 118,846,966.00 141,674,074.00 141,690,850.00 141,701,848.00 141,701,848.00 141,701,848.00
DEI Adjusted Shares Outstanding		 118,846,966.00 118,846,966.00 118,846,966.00 118,846,966.00 141,674,074.00 141,690,850.00 141,701,848.00 141,701,848.00 141,701,848.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.02 -0.17 -0.30 0.10 -0.20 -0.19 -0.15 -0.08 -0.11
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% -99.10% -70.37% -89.39% -99.87% 197.18%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% -604.40% -33.73% 41.29% -231.40% 49.98%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% -583.96% -33.50% 41.12% -234.85% 49.86%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% -409.03% -2.46% 12.51% -105.66% 44.61%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% -1,134.00% -38.47% 41.04% -195.68% 47.57%
EPS Growth		 0.00% 0.00% 0.00% 0.00% -900.00% -35.71% 40.00% -212.50% 45.00%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% -34.63% -302.74% 57.47% 37.09% -26.76%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -461.89%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -71.36% 13.09%
Revenue Q/Q Growth		 0.00% -95.18% 98.15% 1,589.25% -99.44% 57.75% -29.02% -78.62% 1,141.18%
EBITDA Q/Q Growth		 0.00% -401.22% -80.15% 121.95% -455.42% 4.84% 20.91% 50.88% -35.30%
EBIT Q/Q Growth		 0.00% -387.82% -79.62% 121.52% -462.81% 4.79% 20.78% 50.72% -34.90%
NOPAT Q/Q Growth		 0.00% -319.06% -28.26% 79.80% -368.87% 15.65% -9.52% 52.52% -26.29%
Net Income Q/Q Growth		 0.00% -754.46% -79.92% 134.61% -331.91% 4.12% 23.38% 43.84% -27.08%
EPS Q/Q Growth		 0.00% -600.00% -78.57% 132.00% -350.00% 5.00% 21.05% 40.00% -22.22%
Operating Cash Flow Q/Q Growth		 0.00% 40.84% -373.41% -7.32% 55.21% -76.98% 50.00% -58.73% 9.74%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -17.38% 202.50% -92.04% -1,920.29%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -78.73% 15.93% -40.65% 18.91% 9.36%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 82.16% -340.87% -142.92% 91.95% 61.97% 62.05% 59.75% 64.71% 97.39%
EBITDA Margin		 -28.10% -2,924.47% -2,658.88% 34.55% -21,880.99% -13,199.55% -14,706.92% -33,785.29% -3,682.94%
Operating Margin		 -35.55% -3,093.65% -2,002.47% -17.20% -20,006.34% -10,697.77% -16,505.66% -36,650.00% -3,729.15%
EBIT Margin		 -29.07% -2,944.31% -2,668.96% 33.99% -21,978.17% -13,265.63% -14,805.03% -34,117.65% -3,708.06%
Profit (Net Income) Margin		 -14.73% -2,613.10% -2,372.76% 48.61% -20,091.55% -12,211.61% -13,181.13% -34,617.65% -3,544.31%
Tax Burden Percent		 111.80% 101.17% 100.14% 97.43% 100.00% 100.04% 100.00% 100.00% 100.00%
Interest Burden Percent		 45.32% 87.73% 88.78% 146.78% 91.42% 92.02% 89.03% 101.47% 95.58%
Effective Tax Rate		 0.00% 0.00% 0.00% 2.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -58.08% -63.44% -84.04% -87.14% -90.27% -92.56%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 9.13% -3,285.61% -2,181.25% -2,605.18% -114.18% -20.71%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 13.06% -3,003.57% -2,007.94% -2,319.43% -115.85% -19.80%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -58.08% -63.44% -84.04% -87.14% -90.27% -92.56%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.91 -16 -21 -4.24 -20 -17 -18 -8.72 -11
NOPAT Margin		 -24.89% -2,165.56% -1,401.73% -16.76% -14,004.44% -7,488.44% -11,553.96% -25,655.00% -2,610.40%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% 11.23% -12.66% -18.54% -5.06% -2.62% -3.82%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -3.16% -17.64% -17.82% -24.80% -14.00% -22.30%
Cost of Revenue to Revenue		 17.84% 440.87% 242.92% 8.05% 38.03% 37.95% 40.25% 35.29% 2.61%
SG&A Expenses to Revenue		 42.26% 927.12% 513.82% 21.90% 5,411.27% 2,290.63% 3,644.65% 10,982.35% 1,664.93%
R&D to Revenue		 75.45% 1,825.66% 1,345.73% 87.24% 14,657.04% 7,878.13% 12,920.75% 25,732.35% 2,161.61%
Operating Expenses to Revenue		 117.71% 2,752.78% 1,859.55% 109.15% 20,068.31% 10,759.82% 16,565.41% 36,714.71% 3,826.54%
Earnings before Interest and Taxes (EBIT)		 -4.56 -22 -40 8.60 -31 -30 -24 -12 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.41 -22 -40 8.74 -31 -30 -23 -11 -16
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 2.03 1.18 2.91 3.31 4.61 5.04
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 2.19 1.30 3.29 3.88 5.59 6.42
Price to Revenue (P/Rev)		 0.00 0.00 0.00 6.30 4.81 10.08 9.49 513.74 296.69
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 2.89 0.00 5.88 5.53 361.48 213.16
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.00 -1.10 -1.21 -1.21 -1.38 -1.18 -1.27
Leverage Ratio		 0.00 0.00 0.00 2.06 1.64 1.75 1.98 1.70 1.85
Compound Leverage Factor		 0.00 0.00 0.00 3.03 1.50 1.61 1.76 1.73 1.77
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.47 -2.13 -1.63 -2.63 -2.83 -4.23
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 11.14 8.81 10.06 7.69 8.72 9.83
Quick Ratio		 0.00 0.00 0.00 8.82 7.09 7.74 5.88 6.25 6.70
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 0.00 3.90 3.23 9.76 0.78 -14
Operating Cash Flow to CapEx		 0.00% -6,363.53% -40,010.94% -44,324.19% -307,725.00% -45,383.33% -363,033.33% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.57 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -101.69 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -101.69 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.27 0.15 0.16 0.18 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 68.55 675.63 319.64 922.50 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 23.03 16.36 15.31 15.61 0.33 0.54
Accounts Payable Turnover		 0.00 0.00 0.00 0.74 0.48 0.41 0.13 0.01 0.01
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 5.32 0.54 1.14 0.40 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 493.51 757.54 898.13 2,767.71 25,257.15 30,960.28
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 -488.18 -757.00 -896.99 -2,767.32 -25,257.15 -30,960.28
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 -13 -24 -20 -28 -23 -21
Invested Capital Turnover		 0.00 0.00 0.00 -3.25 -2.33 -2.72 -1.84 -0.03 -0.04
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 0.00 -24 -20 -28 -9.50 3.12
Enterprise Value (EV)		 0.00 0.00 0.00 125 -3.36 160 143 202 179
Market Capitalization		 856 753 720 273 133 274 245 287 249
Book Value per Share		 $0.00 $0.00 $0.00 $1.13 $0.80 $0.66 $0.52 $0.44 $0.35
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $1.05 $0.72 $0.59 $0.45 $0.36 $0.27
Total Capital		 0.00 0.00 0.00 134 113 94 74 62 49
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 -147 -137 -114 -102 -85 -70
Capital Expenditures (CapEx)		 0.00 0.09 0.06 0.06 0.00 0.05 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 23 14 20 14 20 22
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 171 151 134 116 105 92
Net Working Capital (NWC)		 0.00 0.00 0.00 171 151 134 116 105 92
Net Nonoperating Expense (NNE)		 -1.59 3.38 15 -17 8.64 11 2.59 3.05 3.94
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -147 -137 -114 -102 -85 -70
Total Depreciation and Amortization (D&A)		 0.15 0.15 0.15 0.14 0.14 0.15 0.16 0.11 0.11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 53.65% 50.51% 72.25% 54.44% 3,565.47% 2,659.59%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 394.25% 543.40% 492.42% 450.07% 18,791.59% 11,012.16%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 394.25% 543.40% 492.42% 450.07% 18,791.59% 11,012.16%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.08 ($0.20) ($0.19) ($0.15) ($0.09) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 138.75M 141.68M 141.70M 141.70M 141.69M 141.70M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.08 ($0.20) ($0.19) ($0.15) ($0.09) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 138.75M 141.68M 141.70M 141.70M 141.69M 141.70M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 141.67M 141.69M 141.70M 141.70M 141.70M 141.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.91 -16 -21 -4.24 -20 -16 -18 -8.72 -11
Normalized NOPAT Margin		 -24.89% -2,165.56% -1,401.73% -16.76% -14,004.44% -7,074.69% -11,553.96% -25,655.00% -2,610.40%
Pre Tax Income Margin		 -13.17% -2,582.94% -2,369.49% 49.90% -20,091.55% -12,207.14% -13,180.50% -34,617.65% -3,544.31%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -68.24 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -51.31 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -68.24 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -51.31 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Silence Therapeutics (NASDAQ: SLN) remains a development-stage biotech with meaningful cash resources, but its recent financial statements show continuing operating losses and heavy cash burn. The company’s balance sheet is still supported by a sizable investment portfolio, yet quarterly operating performance remains far from profitable.

  • SLN ended Q1 2026 with $70.1 million in cash and short-term investments, giving it a substantial liquidity cushion.
  • Total current assets of $102.9 million exceeded total current liabilities of $10.5 million, indicating strong near-term working capital.
  • The company has no debt shown in the provided balance sheet data, which reduces balance sheet risk.
  • Q1 2026 operating cash burn improved versus earlier periods, with net cash from operating activities of -$15.6 million compared with -$17.3 million in Q4 2025.
  • Non-operating investing activity added $10.0 million in Q1 2026, helping offset operating losses and supporting liquidity.
  • Revenue remains very small for a public biotech company, with only $422,000 in Q1 2026 sales.
  • Gross margin is still positive, but the absolute gross profit of $411,000 is too small to cover operating costs.
  • Shares outstanding have been relatively stable around 141.7 million, with little dilution in the most recent quarter.
  • The balance sheet includes $10.4 million of current liabilities and $55.3 million of other noncurrent operating liabilities, so the company still carries meaningful obligations despite its cash position.
  • SLN posted a Q1 2026 net loss of $15.0 million, continuing a long streak of quarterly losses.
  • Operating expenses were $16.1 million in Q1 2026, far above revenue and driving an operating loss of $15.7 million.
  • Cash and short-term investments fell sharply from $102.2 million in Q3 2025 to $70.1 million in Q1 2026, reflecting continued cash usage.
  • Looking back over the last four quarters, operating cash flow has been consistently negative, ranging from roughly -$10.9 million to -$27.5 million.
  • The company’s income statement shows that losses have widened from -$2.3 million in Q1 2024 to -$15.0 million in Q1 2026, underscoring ongoing pressure on profitability.

Bottom line: Silence Therapeutics has enough cash to fund operations in the near term, and its balance sheet is not burdened by debt in the data provided. However, the business is still highly dependent on future clinical or commercial progress because revenue is minimal and losses remain large. Investors should focus on whether future quarters show a sustained reduction in cash burn or a meaningful increase in revenue.

07/10/26 10:10 PM ETAI Generated. May Contain Errors.

Silence Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Silence Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Silence Therapeutics' net income appears to be on an upward trend, with a most recent value of -$88.61 million in 2025, rising from -$23.46 million in 2018. The previous period was -$45.31 million in 2024. See Silence Therapeutics' forecast for analyst expectations on what's next for the company.

Silence Therapeutics' total operating income in 2025 was -$91.08 million, based on the following breakdown:
  • Total Gross Profit: $344 thousand
  • Total Operating Expenses: $91.42 million

Over the last 7 years, Silence Therapeutics' total revenue changed from $0.00 in 2018 to $559 thousand in 2025, a change of 55,900,000.0%.

Silence Therapeutics' total liabilities were at $69.14 million at the end of 2025, a 0.8% increase from 2024, and a 1,317.0% increase since 2018.

In the past 7 years, Silence Therapeutics' cash and equivalents has ranged from $11.28 million in 2025 to $121.33 million in 2024, and is currently $11.28 million as of their latest financial filing in 2025.

Over the last 7 years, Silence Therapeutics' book value per share changed from 0.00 in 2018 to 0.44 in 2025, a change of 44.0%.


Related Companies

Financial statements for NASDAQ:SLN last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Elon’s New Currency (BUY NOW)
Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...
InvestorPlace | Sponsoredtc pixel
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...
Brownstone Research | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Elon’s message for America
Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...
Stansberry Research | Sponsoredtc pixel